Trial Profile
Pilot Study of the Effects of GC811007 Administration on Copper and Trace Metal Metabolism in Non-diabetic Subjects and Patients with Type 2 Diabetes Mellitus: A Dose-response Sub-study of TETA on urinary copper excretion
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Jun 2016
Price :
$35
*
At a glance
- Drugs Trientine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms TRACE-Dose Rising study
- Sponsors Protemix Corporation
- 29 Jun 2016 New trial record